Forschung & Literatur
„‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA“
2023
Yuyang Lei et al,
SARS-CoV-2 Spike Protein Impairs Endothethelial Function via Downregulation of ACE 2,
Circulation Research. 2021; 128: 1323-1326. DOI: 10.1161/CIRCRESAHA. 121.318902 (pdf).
Circulating Spike Protein Detected in Post– COVID-19 mRNA Vaccine Myocarditis
Circulating Spike Protein Detection (pdf)
Literatur
[E.R.D.E. e.V. und E.R.D.E.-AAK-Diagnostik GmbH]
Prevalence and Determinants of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients Screened Positive for Dementia: Results from the Population-Based DelpHi-Study Journal of Alzheimer’s Disease , 64 (2018) 1091–1097, Thyrian et al (PDF), DOI 10.3233/JAD-171096, IOS Press
Role of alpha1-adrenergic receptor antibodies in Alzheimer‘s diseases, Frontiers In Bioscience, Landmark, 23, 2082-2089, June 1, 2018, Karczewskil et al (PDF), DOI No:102741/4691 PubMed No1
Immunoadsorption in Buerger’s Disease (Thromboangiitis Obliterans A Promising Therapeutic Option: Result of a Consecutive Patient Cohort Treated in Clinical Routine Care Lupus Open-Accesss 2016, Klein-Weigell et al (PDF).
Immunoadsorption of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients with Mild to Moderate Dementia, Therapeutic Apheresis and Dialysis 2016, Hempel et al (PDF).
Vaskuläre Komplikationen durch Autoantikörper gegen G-Protein gekoppelte Rezeptoren bei den Volkskrankheiten Demenz und Typ-2-Diabetes sowie der Bürgerschen Krankheit archiv, euromedica 2015, Peter Karczewski et al (PDF).
G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger’s disease) and their removal by immunoadsorption,Vasa 2014, Peter F. Klein-Weigel et al (PDF).
Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α1-adrenergic receptor antibodies, NMR in Biomedicine 2014, Andreas Pohlmann et al (PDF).
New targets for clinical application of apheresis,ICB Seminar 2014, R. Kunze et al (PDF).
Antibodies to the α1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography, PloS One 2012, Peter Karczewski et al (PDF).
Autoantibodies to the α1-adrenergic receptor and the β2-adrenergic receptor in Alzheimer’s and vascular dementia, Scandinavian Journal of Immunology 2011, Peter Karczewski et al (PDF).
Sera from patients with type 2 diabetes contain agonistic autoantibodies against G protein-coupled receptors, Scandinavian Journal of Immunology 2009, Petra Hempel et al (PDF).
Agonistic antibody to the α1-adrenergic receptor mobilizes intra cellular calcium and induces phosphorylation of acardiac 15-kDa protein, MolCellBiochem2009, Peter Karczewski et al (PDF).
Potential relevance of α1-adrenergic receptor autoantibodies in refractory hypertension, PloS One 2008, Katrin Wenzel et al (PDF).
Agonistic Autoantibodies, a Risk Factor in Patients with Type 2 Diabetes, archive euromedica 2019, vol. 9(1): 98–102, Bimmler et al (PDF).
EU-Patent: Bimmler et al, 02.08.2017 (Patent No. EP 2 742 065 B1)
US-Patent: Bimmler et al, 18.07.2017 (Patent No. US 9 708 372 B2)